Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study
BackgroundRituximab (RTX) is gaining increasing clinical acceptance in the treatment of primary membranous nephropathy (PMN), with demonstrated efficacy and safety. However, there are few clinical studies on RTX for PMN in Asian populations, especially in China.MethodsTo observe and analyse the effi...
Shranjeno v:
| Principais autores: | , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2023-04-01
|
| Serija: | Frontiers in Immunology |
| Teme: | |
| Online dostop: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1156470/full |
| Oznake: |
Brez oznak, prvi označite!
|